March 18, 2020 / 7:50 AM / 17 days ago

BRIEF-Pharnext Says PXT3003 For Treatment Of Charcot-Marie-Tooth Disease Type 1A Granted PIM Designation

March 18 (Reuters) - PHARNEXT SA:

* PHARNEXT ANNOUNCES PXT3003 FOR TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE TYPE 1AHAS BEEN GRANTED PIM DESIGNATION BY UK MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY

* PIM DESIGNATION IS EARLY INDICATION THAT MEDICINAL PRODUCT IS PROMISING CANDIDATE FOR EARLY ACCESS TO MEDICINES SCHEME (EAMS) IN TREATMENT, DIAGNOSIS OR PREVENTION OF LIFE-THREATENING OR SERIOUSLY DEBILITATING CONDITIONS WITH UNMET NEED

* WE LOOK FORWARD TO CONTINUING OUR DISCUSSIONS WITH U.S. AND EUROPEAN REGULATORY AUTHORITIES TO ADVANCE THE CLINICAL DEVELOPMENT - CEO Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below